University of Cincinnati

Catherine Behrmann

David Plas

Methods for targeting adaptive responses to chemotherapy are described. In various embodiments, a method comprises administering at least one compound that inhibits S6K1, mTORC1 or upstream or downstream pathway components of S6K1 or mTORC1, in association with administration of at least one inhibitor of PPAR&#x3b1;, PPAR&#x3b4;, or PGC1&#x3b1;. In various embodiments, the compound that inhibits S6K1, mTORC1, or upstream or downstream pathway components of S6K1 or mTORC1 is rapamycin, everolimus, temsirolimus, or imatinib. The inhibitor of PPAR&#x3b1;, PPAR&#x3b4;, or PGC1&#x3b1; can be an antagonist or an inverse agonist selected from GW6471, GSK3787, GSK0660, and ST247.

Growing community of inventors

Fairfield, OH, United States of America

Catherine Behrmann